«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:

2019年04期

页码:

345-249

栏目:

临床研究

出版日期:

2019-09-27

文章信息/Info

Title:

The effect of IL-35 on the activation of human umbilical vein endothelial cells induced by sCD40L

作者:

郭巍巍 陈杰 钱雷 李明

224500 滨海县人民医院介入科(郭巍巍),心内科(陈杰),检验科(钱雷,李明)

Author(s):

GUO Weiwei¹;  CHEN Jie²;  QIAN Lei³;  LI Ming³

1.Department of Interventional,People's Hospital of Binhai County,Jiangsu 224500; 2.Department of Cardiology,People's Hospital of Binhai County,Jiangsu 224500; 3. Laboratory Medicine, People's Hospital of Binhai County, Jiangsu 224500, China

关键词:

白细胞介素-35;  可溶性CD40配体;  冠状动脉粥样硬化性心脏病;  人脐静脉血管内皮细胞

Keywords:

Interleukin-35;  Soluble CD40 ligand;  Coronary heart disease;  Human umbilical vein endothelial cells

分类号:

-

DOI:

10.3969/j.issn.1673-6583.2019.04.015

文献标识码:

-

摘要:

目的:探讨白细胞介素(IL)-35对可溶性CD40配体(sCD40L)诱导人脐静脉血管内皮细胞(HUVEC)活化的作用及IL-35和sCD40L在冠状动脉粥样硬化性心脏病(冠心病)发病过程中的作用。方法:入选43例冠心病患者,其中不稳定型心绞痛20例(UA组),急性ST段抬高型心机梗死23例(STEMI组),20例健康体检者设为对照组,酶联免疫吸附试验(ELISA)检测外周血清IL-35和sCD40L水平,并分析两者的相关性。体外培养HUVEC,分为空白组、sCD40L组、IL-35+sCD40L组,EL

Abstract:

Objective:To explore the effect of interleukin(IL)-35 on the activation of human umbilical vein endothelial cells(HUVEC)induced by soluble CD40 ligand(sCD40L)and the role of IL-35 and sCD40L in the pathogenesis of coronary heart disease(CHD).Methods:IL-35

参考文献/References

[ 1 ] Chen J, Li JH, Zhao SJ, et al. Clinical significance of costimulatory molecules CD40/CD40L and CD134/CD134L in coronary heart disease: a case-control study[J]. Medicine(Baltimore), 2017, 96(32):e7634.
[ 2 ] Gutiérrez E, Flammer AJ, Lerman LO, et al. Endothelial dysfunction over the course of coronary artery disease[J]. Eur Heart J, 2013, 34(41):3175-3181.
[ 3 ] 马彩云, 柳景华, 马芹, 等. 冠心病与血管内皮细胞标志物关系的研究[J]. 中国介入心脏病学杂志, 2016, 24(2):104-106.
[ 4 ] Yuan M, Fu H, Ren L, et al. Soluble CD40 ligand promotes macrophage foam cell formation in the etiology of atherosclerosis[J]. Cardiology, 2015, 131(1):1-12.
[ 5 ] Sha XJ, Meng S, Li XY, et al. Interleukin-35 inhibits endothelial cell activation by suppressing MAPK-AP-1 pathway[J]. J Biol Chem, 2015, 290(31):19307-19318.
[ 6 ] 陈灏珠. 心脏病学[M]. 7版. 北京: 人民卫生出版社, 2007:275-278.
[ 7 ] 李影, 刘素芬, 齐强, 等. 急性冠脉综合征患者内皮损伤的临床研究进展[J]. 临床合理用药杂志, 2016, 9(16):176-177.
[ 8 ] Li H, Sun K, Zhao R, et al. Inflammatory biomarkers of coronary heart disease[J]. Front Biosci(Schol Ed), 2018, 10:185-196.
[ 9 ] Bäck M, Weber C, Lutgens E. Regulation of atherosclerotic plaque inflammation[J]. J Intern Med, 2015, 278(5):462-482.
[10] Chakrabarti S, Rizvi M, Pathak D, et al. Hypoxia influences CD40-CD40L mediated inflammation in endothelial and monocytic cells[J]. Immunol Lett, 2009, 122(2):170-184.
[11] Zhang B, Wu T, Chen M, et al. The CD40/CD40L system: a new therapeutic target for disease[J]. Immunol Lett, 2013, 153(1/2):58-61.
[12] 邹美娜, 毕国荣. 可溶性CD40配体与心脑血管疾病关系的研究进展[J]. 实用心脑肺血管病杂志, 2016, 24(4):5-8.
[13] Heeschen C, Dimmeler S, Hamm CW. Soluble CD40 ligand in acute coronary syndromes[J]. ACC Curr J Rev, 2003, 12(3):12-13.
[14] Fouad HH, Al-Dera H, Bakhoum SW, et al. Levels of sCD40 ligand in chronic and acute coronary syndromes and its relation to angiographic extent of coronary arterial narrowing[J]. Angiology, 2010, 61(6):567-573.
[15] Bobryshev YV, Sobenin IA, Orekhov AN. Novel Anti-inflammatory interleukin-35 as an emerging target for anti-atherosclerotic therapy[J]. Curr Pharm Des, 2015, 21(9):1147-1151.
[16] Lin Y, Huang Y, Lu Z, et al. Decreased plasma IL-35 levels are related to the left ventricular ejection fraction in coronary artery diseases[J]. PLoS One, 2012, 7(12):e52490.
[17] Mor A, Luboshits G, Planer D, et al. Altered status of CD4(+)CD25(+)regulatory T cells in patients with acute coronary syndromes[J]. Eur Heart J, 2006, 27(21):2530-2537.
[18] 刘红利, 位庚, 李红蓉, 等. 通心络对活化血小板诱导人脐静脉内皮细胞的保护作用[J]. 中成药, 2016, 38(9):2035-2038.

备注/Memo

备注/Memo:

作者单位:224500 滨海县人民医院介入科(郭巍巍),心内科(陈杰),检验科(钱雷,李明)
通信作者:李明,Email:liming861026@163.com

常用功能

更新日期/Last Update: 2019-09-27